Press Releases
Our latest happenings and recent highlights.
For media inquiries, please contact: daniel.salvo@omniabio.com
Featured
HAMILTON & TORONTO ONTARIO – December 23, 2025 – OmniaBio Inc., Canada’s largest cell and gene therapy (CGT) contract development and manufacturing organization (CDMO), today announced that Health Canada has awarded the company a Drug Establishment License (DEL), confirming the maturity and compliance of its Good Manufacturing Practices (GMP). Secured less than one year after...
June 12, 2024 (Hamilton, Ontario) – OmniaBio Inc. is pleased to announce the appointment of Kenneth (Ken) L. Harris as its Chief Strategy Officer and Head of Artificial Intelligence (AI), strengthening its mandate of bringing...
15 New projects underway to build world leading advanced manufacturing capabilities in Canada.TORONTO, ON, February 8, 2024 - NGen has announced over $32.3 million in Global Innovation Cluster funding for 15 new advanced manufacturing projects....
CCRM Australia, with its Canadian partners OmniaBio Inc. and Toronto-based CCRM, has signed a Letter of Intent with The University of Queensland to establish the Advanced Cell Therapy Manufacturing Initiative (ACTMI)...
The Canadian Advanced Therapies Training Institute (CATTI) Inc. has launched its first in-person training site at the University of Guelph...
Catamaran Bio Inc., a biotechnology company developing off-the-shelf NK cell therapies to treat cancer, and OmniaBio Inc., a CDMO focused on...
OmniaBio Inc. has expanded its footprint by adding a new process and analytical development lab space at the McMaster University Medical Centre (MUMC)...